Autolus Therapeutics announced that it intends to file a notification of late filing with the Securities and Exchange Commission later this week with regard to its quarterly report for the quarter ended March 31, 2024. The filing will allow the company an automatic extension of five additional calendar days to file report, which is due on May 15. In accordance with today’s announcement, the company is canceling its previously announced earnings release and call scheduled for before U.S. market open on May 14.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics Announces Q1 2024 Financial Update
- AUTL Earnings this Week: How Will it Perform?
- Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
- Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Autolus Therapeutics price target raised to $11 from $10 at Truist